Fly News Breaks for January 10, 2020
Jan 10, 2020 | 08:11 EDT
Maxim analyst Jason McCarthy raised his price target on Cassava Sciences shares to $12 from $3, stating that he expects shares could continue to rise in value through 2020 as activity in the Alzheimer's disease space continues to heat up. He believes insider buying, the Phase 2a data, and expectations around Cassava's Phase 2b trial in 2020 have all played a hand in the stock's significant rise in value since mid-December, added McCarthy, who keeps a Buy rating on the stock.
News For SAVA From the Last 2 Days
There are no results for your query SAVA